| dbo:abstract
|
- كلازاكيزوماب (بي إم إس - 945429 (بالإنجليزية: BMS-945429) وأيه إل دي 518 (بالإنجليزية: ALD518) سابقاً) هو جسم مضاد وحيد النسيلة يعمل مضاداً لإنترلوكن-6. ما زال دواءً تجريبياً من المفترض استخدامه لعلاج السرطان والتهاب المفاصل الروماتويدي وداء كرون بسبب مواصفاته المضادة للالتهاب. طورته وبريستول مايرز سكويب. (ar)
- Clazakizumab (formerly ALD518 and BMS-945429), an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6. Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect. (en)
- L'ALD518 ora BMS-945.429 è un anticorpo monoclonale umanizzato aglicosilato, attivo contro l'interleuchina-6. Si tratta di un farmaco sperimentale per il cancro e l'artrite reumatoide ciò grazie alle sue proprietà anti-infiammatorie. L'emivita relativamente lunga, circa 30 giorni, dovrebbe consentire la riduzione delle frequenti iniezioni sottocutanee. Viene realizzato con cellule di lievito piuttosto che secondo lo standard con delle cellule ovariche di criceto cinese. (it)
|
| dbo:casNumber
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 2353 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:h
| |
| dbp:kegg
| |
| dbp:legalStatus
| |
| dbp:mabType
| |
| dbp:n
| |
| dbp:o
| |
| dbp:routesOfAdministration
| |
| dbp:s
| |
| dbp:source
| |
| dbp:synonyms
| |
| dbp:target
| |
| dbp:type
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- كلازاكيزوماب (بي إم إس - 945429 (بالإنجليزية: BMS-945429) وأيه إل دي 518 (بالإنجليزية: ALD518) سابقاً) هو جسم مضاد وحيد النسيلة يعمل مضاداً لإنترلوكن-6. ما زال دواءً تجريبياً من المفترض استخدامه لعلاج السرطان والتهاب المفاصل الروماتويدي وداء كرون بسبب مواصفاته المضادة للالتهاب. طورته وبريستول مايرز سكويب. (ar)
- Clazakizumab (formerly ALD518 and BMS-945429), an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6. Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect. (en)
- L'ALD518 ora BMS-945.429 è un anticorpo monoclonale umanizzato aglicosilato, attivo contro l'interleuchina-6. Si tratta di un farmaco sperimentale per il cancro e l'artrite reumatoide ciò grazie alle sue proprietà anti-infiammatorie. L'emivita relativamente lunga, circa 30 giorni, dovrebbe consentire la riduzione delle frequenti iniezioni sottocutanee. Viene realizzato con cellule di lievito piuttosto che secondo lo standard con delle cellule ovariche di criceto cinese. (it)
|
| rdfs:label
|
- كلازاكيزوماب (ar)
- Clazakizumab (en)
- BMS-945429 (it)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |